Sonrotoclax Plus Zanubrutinib Achieves >90% uMRD in Treatment-Naive CLL/SLL
The all-oral combination of sonrotoclax (BGB-11417) and zanubrutinib (Brukinsa) produced undetectable minimal residual disease (uMRD) rates exceeding 90%…
Browsing Category